Skip to main content

Uplizna FDA Approval History

Last updated by Judith Stewart, BPharm on April 14, 2025.

FDA Approved: Yes (First approved June 11, 2020)
Brand name: Uplizna
Generic name: inebilizumab-cdon
Dosage form: Injection
Company: Viela Bio
Treatment for: Neuromyelitis Optica Spectrum Disorder, Immunoglobulin G4-Related Disease

Uplizna (inebilizumab-cdon) is a CD19-directed cytolytic antibody used for the treatment of neuromyelitis optica spectrum disorder and immunoglobulin G4-related disease.

Development timeline for Uplizna

DateArticle
Apr  3, 2025Approval Uplizna (inebilizumab-cdon) is Now the First and Only FDA-Approved Treatment for IgG4-Related Disease
Jun 13, 2020Approval FDA Approves Uplizna (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.